#ESMOGynae26: Data from two #ClinicalTrials provide long-term #EfficacyAndSafety evidence for the #CheckpointInhibitor dostarlimab, suggesting that immunotherapy may be used with curative intent in #EndometrialCancer. #ESMODailyReporter➡️ https://ow.ly/Mqq150ZefWk
June 18, 2026 at 2:45 PM
#ESMOGynae26: Data from two #ClinicalTrials provide long-term #EfficacyAndSafety evidence for the #CheckpointInhibitor dostarlimab, suggesting that immunotherapy may be used with curative intent in #EndometrialCancer. #ESMODailyReporter➡️ https://ow.ly/Mqq150ZefWk